Literature DB >> 24772255

Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents.

Seung-Woon Rha1.   

Abstract

Current percutaneous coronary intervention guidelines recommend dual antiplatelets (aspirin 100 mg + clopidogrel 75 mg daily) for at least 12 mo following drug-eluting stent (DES) implantation if patients are not at high risk of bleeding. Several reports have tried to shorten the dual antiplatelet therapy to 3-6 mo, especially following next-generation DES implantation, for cost-effectiveness. However, the clinical results are inconsistent and the data regarding next-generation DESs limited. In this report, recently published important pivotal reports regarding the optimal duration of dual antiplatelets following DES implantation are summarized.

Entities:  

Keywords:  Drug-eluting stent; Dual antiplatelet treatment; Percutaneous coronary intervention

Year:  2014        PMID: 24772255      PMCID: PMC3999335          DOI: 10.4330/wjc.v6.i4.148

Source DB:  PubMed          Journal:  World J Cardiol


  22 in total

1.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.

Authors:  Duk-Woo Park; Seong-Wook Park; Kyoung-Ha Park; Bong-Ki Lee; Young-Hak Kim; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2006-06-12       Impact factor: 2.778

2.  Pathways of platelet activation and unexplained clopidogel variability: causes of poor response to clopidogrel.

Authors:  Nicholas G Kounis; Nicholas Grapsas
Journal:  Thromb Res       Date:  2013-05-26       Impact factor: 3.944

3.  A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

Authors:  Clemens von Birgelen; Mounir W Z Basalus; Kenneth Tandjung; K Gert van Houwelingen; Martin G Stoel; J Hans W Louwerenburg; Gerard C M Linssen; Salah A M Saïd; Miep A W J Kleijne; Hanim Sen; Marije M Löwik; Job van der Palen; Patrick M J Verhorst; Frits H A F de Man
Journal:  J Am Coll Cardiol       Date:  2012-02-15       Impact factor: 24.094

4.  Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation.

Authors:  Jun-ichi Kotani; Yuji Ikari; Eishou Kyo; Masato Nakamura; Hiroyoshi Yokoi
Journal:  Intern Med       Date:  2013-04-01       Impact factor: 1.271

5.  Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Authors:  Hyeon-Cheol Gwon; Joo-Yong Hahn; Kyung Woo Park; Young Bin Song; In-Ho Chae; Do-Sun Lim; Kyoo-Rok Han; Jin-Ho Choi; Seung-Hyuk Choi; Hyun-Jae Kang; Bon-Kwon Koo; Taehoon Ahn; Jung-Han Yoon; Myung-Ho Jeong; Taek-Jong Hong; Woo-Young Chung; Young-Jin Choi; Seung-Ho Hur; Hyuck-Moon Kwon; Dong-Woon Jeon; Byung-Ok Kim; Si-Hoon Park; Nam-Ho Lee; Hui-Kyung Jeon; Yangsoo Jang; Hyo-Soo Kim
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

6.  Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

Authors:  Cheol Whan Lee; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seungbong Han; Sang-Gon Lee; In-Whan Seong; Seung-Woon Rha; Myung-Ho Jeong; Do-Sun Lim; Jung-Han Yoon; Seung-Ho Hur; Yun-Seok Choi; Joo-Young Yang; Nae-Hee Lee; Hyun-Sook Kim; Bong-Ki Lee; Kee-Sik Kim; Seung-Uk Lee; Jei-Keon Chae; Sang-Sig Cheong; Il-Woo Suh; Hun-Sik Park; Deuk-Young Nah; Doo-Soo Jeon; Ki-Bae Seung; Keun Lee; Jae-Sik Jang; Seung-Jung Park
Journal:  Circulation       Date:  2013-10-04       Impact factor: 29.690

7.  Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.

Authors:  Marco Valgimigli; Seung-Jung Park; Hyo-Soo Kim; Kyung Woo Park; Duk-Woo Park; Pierluigi Tricoci; Giuseppe Ferrante
Journal:  Int J Cardiol       Date:  2013-04-13       Impact factor: 4.164

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.

Authors:  Ian T Meredith; Stephen Worthley; Robert Whitbourn; Darren L Walters; Dougal McClean; Mark Horrigan; Jeffrey J Popma; Donald E Cutlip; Ann DePaoli; Manuela Negoita; Peter J Fitzgerald
Journal:  JACC Cardiovasc Interv       Date:  2009-10       Impact factor: 11.195

10.  Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.

Authors:  Takeshi Kimura; Takeshi Morimoto; Yoshihisa Nakagawa; Toshihiro Tamura; Kazushige Kadota; Hitoshi Yasumoto; Hideo Nishikawa; Yoshikazu Hiasa; Toshiya Muramatsu; Taiichiro Meguro; Naoto Inoue; Hidehiko Honda; Yasuhiko Hayashi; Shunichi Miyazaki; Shigeru Oshima; Takashi Honda; Nobuo Shiode; Masanobu Namura; Takahito Sone; Masakiyo Nobuyoshi; Toru Kita; Kazuaki Mitsudo
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

View more
  1 in total

1.  In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.

Authors:  Meike-Kristin Abraham; Andrea Nolte; Rebekka Reus; Andreas Behring; Diane Zengerle; Meltem Avci-Adali; Jan David Hohmann; Karlheinz Peter; Christian Schlensak; Hans Peter Wendel; Stefanie Krajewski
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.